Nasopharyngeal carcinoma: The next challenges

European Journal of Cancer

Volumn 46, Issue 11, 2010, Pages 1967-1978

  Razak, Albiruni R A ^a   Siu, Lillian L ^a   Liu, Fei Fei ^b   Ito, Emma ^b   O'Sullivan, Brian ^b   Chan, Kelvin ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell lines; Chemotherapy; Molecularly targeted therapy; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC METAL COMPLEX; AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPSTEIN BARR VIRUS VACCINE; ERLOTINIB; EVEROLIMUS; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; GEMCITABINE; HISTONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; PHOSPHATIDYLINOSITOL 3 KINASE; ROSCOVITINE; SCATTER FACTOR RECEPTOR; SORAFENIB; TRIPHOSPHOINOSITIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VORINOSTAT;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; COUGHING; DEACETYLATION; DRUG UPTAKE; ENZYME INHIBITION; EPIGENETICS; EPSTEIN BARR VIRUS; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LOADING DRUG DOSE; METHYLATION; MOLECULAR THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; OTOTOXICITY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW; SIDE EFFECT; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; HUMANS; IMMUNOTHERAPY; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS;

EID: 77954219503     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.04.004     Document Type: Article

References (144)

1. D. Jeannel, and G.A.H. Bouvier Nasopharyngeal carcinoma: an epidemiological approach to carcinogenesis Cancer Surv 33 1999 125 155
2. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
3. J.M. Yuan, X.L. Wang, and Y.B. Xiang Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China Int J Cancer 85 2000 358 363
4. D.C. Farrow, T.L. Vaughan, and M. Berwick Diet and nasopharyngeal cancer in a low-risk population Int J Cancer 78 1998 675 679
5. D. Liebowitz Nasopharyngeal carcinoma: the Epstein-Barr virus association Semin Oncol 21 1994 376 381
6. K.W. Lo, and D.P. Huang Genetic and epigenetic changes in nasopharyngeal carcinoma Semin Cancer Biol 12 2002 451 462
7. G. Henle, and W. Henle Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma Int J Cancer 17 1976 1 7
8. R. Pathmanathan, U. Prasad, R. Sadler, K. Flynn, and N. Raab-Traub Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma New Engl J Med 333 1995 693 698
9. Y.C. Chien, J.Y. Chen, and M.Y. Liu Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men New Engl J Med 345 2001 1877 1882
10. H. zur Hausen, H. Schulte-Holthausen, and G. Klein EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx Nature 228 1970 1056 1058
11. M.M. Hsu, and S.M. Tu Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy Cancer 52 1983 362 368
12. E.E. Vokes, D.N. Liebowitz, and R.R. Weichselbaum Nasopharyngeal carcinoma Lancet 350 1997 1087 1091
13. M. Al-Sarraf, M. LeBlanc, and P.G. Giri Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 J Clin Oncol 16 1998 1310 1317
14. J. Wee, E.H. Tan, and B.C. Tai Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety J Clin Oncol 23 2005 6730 6738
15. E.P. Hui, S.F. Leung, and J.S. Au Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group Cancer 101 2004 300 306
16. A.W. Lee, W.M. Sze, and J.S. Au Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience Int J Radiat Oncol 61 2005 1107 1116
17. N. Lee, P. Xia, and J.M. Quivey Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience Int J Radiat Oncol 53 2002 12 22
18. S.F. Leung, B. Zee, and B.B. Ma Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma J Clin Oncol 24 2006 5414 5418
19. J.C. Lin, W.Y. Wang, and K.Y. Chen Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma New Engl J Med 350 2004 2461 2470
20. Y.M. Lo, A.T. Chan, and L.Y. Chan Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA Cancer Res 60 2000 6878 6881
21. M.T. Liu, and C.Y. Yeh Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC) Radiat Med 16 1998 113 117
22. C.W. Twu, W.Y. Wang, and W.M. Liang Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma Int J Radiat Oncol 67 2007 130 137
23. A trial of adjuvant chemotherapy in nasopharyngeal carcinoma patients with residual Epstein-Barr virus (EBV) DNA following radiotherapy. < http://www.clinicaltrials.gov > [Accessed 11.03.10].
24. E. Felip, and R. Rosell Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response Exp Rev Mol Diagn 7 2007 261 268 (Pubitemid 46798616)
25. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy New Engl J Med 355 2006 983 991
26. M. Cobo, D. Isla, and B. Massuti Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J Clin Oncol 25 2007 2747 2754
27. J. Viguier, V. Boige, and C. Miquel ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer Clin Cancer Res 11 2005 6212 6217
28. B.B. Ma, E.P. Hui, and S.C. Wong Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma - correlation with excision repair cross-complementing-1 polymorphisms Ann Oncol 20 2009 1854 1859
29. J.Y. Blay, S. Bonvalot, and P. Casali Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 2005 566 578
30. S.W. Lee, S.Y. Nam, and K.C. Im Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas Radiother Oncol 87 2008 211 216
31. T.C. Yen, C.Y. Lin, and H.M. Wang 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma Int J Radiat Oncol 65 2006 1307 1314
32. T. Liu, W. Xu, and W.L. Yan FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review Radiother Oncol 85 2007 327 335
33. R.I. Freshney Authentication of cell lines: ignore at your peril! Exp Rev Anticancer Ther 8 2008 311 314
34. S.M. Gartler Genetic markers as tracers in cell culture Natl Cancer Inst Monogr 26 1967 167 195
35. K. Takaoka, H. Kishimoto, and E. Segawa Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA Int J Oncol 29 2006 1095 1101
36. J. Phuchareon, Y. Ohta, J.M. Woo, D.W. Eisele, and O. Tetsu Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2 PloS One 4 2009 e6040
37. S.Y. Chan, K.W. Choy, and S.W. Tsao Authentication of nasopharyngeal carcinoma tumor lines Int J Cancer 122 2008 2169 2171
38. J.R. Masters, J.A. Thomson, and B. Daly-Burns Short tandem repeat profiling provides an international reference standard for human cell lines Proc Natl Acad Sci 98 2001 8012 8017
39. S.T. Cheung, D.P. Huang, and A.B. Hui Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus Int J Cancer 83 1999 121 126
40. E. Chiong, A. Dadbin, L.D. Harris, A.L. Sabichi, and H.B. Grossman The use of short tandem repeat profiling to characterize human bladder cancer cell lines J Urol 181 2009 2737 2748
41. K. Yoshino, E. Iimura, and K. Saijo Essential role for gene profiling analysis in the authentication of human cell lines Human Cell 19 2006 43 48
42. J. Potash, and K.C. Anderson What's your line? Clin Cancer Res 15 2009 4251
43. K.W. Lo, K.F. To, and D.P. Huang Focus on nasopharyngeal carcinoma Cancer Cell 5 2004 423 428
44. J.L. Leong, K.S. Loh, T.C. Putti, B.C. Goh, and L.K. Tan Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx Laryngoscope 114 2004 153 157
45. M. Fujii, T. Yamashita, R. Ishiguro, M. Tashiro, and K. Kameyama Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma Auris, Nasus, Larynx 29 2002 175 181
46. Y. Segawa, Y. Oda, and H. Yamamoto Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma Oncol Rep 21 2009 1197 1202
47. S.M. Krishna, S. James, and P. Balaram Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status Virus Res 115 2006 85 90
48. Y.H. Li, C.F. Hu, and Q. Shao Elevated expressions of survivin, VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma J Transl Med 6 2008 1
49. J. Yan, Y. Fang, and B.J. Huang Absence of evidence for HER2 amplification in nasopharyngeal carcinoma Cancer Gen Cytogen 132 2002 116 119
50. B.B. Ma, T.C. Poon, and K.F. To Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study Head Neck 25 2003 864 872
51. C.C. Chou, M.J. Chou, and C.Y. Tzen PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival Med Oncol 26 2009 322 326
52. Y.Y. Or, A.B. Hui, K.F. To, C.N. Lam, and K.W. Lo PIK3CA mutations in nasopharyngeal carcinoma Int J Cancer 118 2006 1065 1067
53. A. Fendri, A. Khabir, and W. Mnejja PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma Cancer Sci 100 2009 2034 2039
54. A.B. Hui, Y.Y. Or, and H. Takano Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma Cancer Res 65 2005 8125 8133
55. C.N. Qian, X. Guo, and B. Cao Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma Cancer Res 62 2002 589 596
56. G. Bar-Sela, A. Kuten, S. Ben-Eliezer, E. Gov-Ari, and O. Ben-Izhak Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach Mod Pathol 16 2003 1035 1040
57. C.M. Chan, B.B. Ma, and E.P. Hui Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma - a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor Oral Oncol 43 2007 373 378
58. W.K. Yip, V.C. Leong, M.A. Abdullah, S. Yusoff, and H.F. Seow Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma Oncology Rep 19 2008 319 328
59. E.P. Hui, A.T. Chan, and F. Pezzella Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival Clin Cancer Res 8 2002 2595 2604
60. J. Pan, L. Kong, and S. Lin The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma Laryngoscope 118 2008 1970 1975
61. D.T. Chua, J.M. Nicholls, J.S. Sham, and G.K. Au Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy Int J Radiat Oncol 59 2004 11 20
62. Y. Tao, X. Song, and X. Deng Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1 Exp Cell Res 303 2005 240 251
63. C.P. Kung, and N. Raab-Traub Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3 J Virol 82 2008 5486 5493
64. N.J. Thornburg, and N. Raab-Traub Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes J Virol 81 2007 12954 12961
65. N. Ma, M. Kawanishi, and Y. Hiraku Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression Int J Cancer 122 2008 2517 2525
66. D.T. Chua, W.I. Wei, and M.P. Wong Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma Head Neck 30 2008 863 867
67. B. Ma, E.P. Hui, and A. King A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy Cancer Chemother Pharmacol 62 2008 59 64
68. A.T. Chan, M.M. Hsu, and B.C. Goh Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma J Clin Oncol 23 2005 3568 3576
69. B. You, C. Le Tourneau, and E. Chen A phase II trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and/or metastatic nasopharyngeal carcinoma (NPC) Eur J Cancer Suppl 7 2009 478
70. B.B. Ma, S.F. Leung, and M.K. Kam A phase II study of concurrent cetuximab-cisplatin, intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) J Clin Oncol 26 2008 6055 [abstract]
71. Study of cetuximab in nasopharyngeal carcinoma (NPC) with chemoradiotherapy (ENCORE). < http://www.clinicaltrials.gov > [accessed 14.03.10].
72. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New Engl J Med 354 2006 567 578
73. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2009 21 28
74. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer New Engl J Med 359 2008 1116 1127
75. C.Q. Zhu, G. da Cunha Santos, and K. Ding Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 2008 4268 4275
76. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma New Engl J Med 361 2009 947 957
77. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer New Engl J Med 361 2009 958 967
78. Merlano MC, Numico G, Russi EG, et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study. J Clin Oncol 2007;25(18s):6043 [abstract].
79. Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008;26(May 20 Suppl):6006 [abstract].
80. J.D. O'Neil, T.J. Owen, and V.H. Wood Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro J Gen Virol 89 2008 2833 2842
81. D. Stevenson, C. Charalambous, and J.B. Wilson Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9 Cancer Res 65 2005 8826 8835
82. C. Elser, L.L. Siu, and E. Winquist Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 2007 3766 3773
83. N. Wakisaka, Q.H. Wen, and T. Yoshizaki Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma Laryngoscope 109 1999 810 814
84. Bevacizumab, cisplatin, radiation therapy, and fluorouracil in treating patients with stage IIB, stage III, stage IVA, or stage IVB nasopharyngeal cancer. < http://www.clinicaltrials.gov > [accessed 10.02.10].
85. Wolmark N, Yothers G, O'Connell M, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009;27(18s):LBA4 [abstract].
86. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer New Engl J Med 360 2009 563 572
87. J.P. Eder, G.F. Vande Woude, S.A. Boerner, and P.M. LoRusso Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin Cancer Res 15 2009 2207 2214
88. T. Horikawa, T.S. Sheen, and H. Takeshita Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma Am J Pathol 159 2001 27 33 (Pubitemid 33704188)
89. M. Jo, D.B. Stolz, and J.E. Esplen Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells J Biol Chem 275 2000 8806 8811
90. J.A. Morrison, M.L. Gulley, R. Pathmanathan, and N. Raab-Traub Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma Cancer Res 64 2004 5251 5260
91. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
92. Ma BB, Lui VW, Hui EP, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs; 2009 [Epub ahead of print].
93. L. Yang, L. Xiao, and X. Ma Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma Cancer Biol Ther 8 2009 366 371
94. B.B. Ma, E.P. Hui, and A.T. Chan Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions Cancer Sci 99 2008 1311 1318
95. L. Xueguan, W. Xiaoshen, and Z. Yongsheng Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide Clin Oncol 20 2008 606 612
96. S. Kondo, S.Y. Seo, and T. Yoshizaki EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells Cancer Res 66 2006 9870 9877
97. N. Wakisaka, S. Kondo, and T. Yoshizaki Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha Mol Cell Biol 24 2004 5223 5234
98. Diaz-Padilla I, Siu LL, Duran I. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs; 2009 [Epub ahead of print].
99. K.W. Lo, D.P. Huang, and K.M. Lau P16 gene alterations in nasopharyngeal carcinoma Cancer Res 55 1995 2039 2043
100. X. Song, Y.G. Tao, and L. Zeng Latent membrane protein 1 encoded by Epstein-Barr virus modulates directly and synchronously cyclin D1 and p16 by newly forming a c-Jun/Jun B heterodimer in nasopharyngeal carcinoma cell line Virus Res 113 2005 89 99
101. A.A. Li, E. Ng, and W. Shi Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma Int J Cancer 110 2004 452 458 (Pubitemid 38649900)
102. A.B. Hui, S. Yue, and W. Shi Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma Clin Cancer Res 15 2009 3716 3724
103. W.S. Hsieh, R. Soo, and B.K. Peh Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer Clin Cancer Res 15 2009 1435 1442
104. W. Yeo, B. Goh, and C. Le Tourneau A phase II randomized study of oral selicilib in patients with previously treated nasopharyngeal carcinoma J Clin Oncol 27 18s 2009 6026
105. L.S. Chow, K.W. Lo, and J. Kwong RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma Int J Cancer 109 2004 839 847
106. A.B. Hui, K.W. Lo, and S.F. Leung Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation Int J Cancer 82 1999 498 503
107. G.L. Wang, K.W. Lo, and K.S. Tsang Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma Brit J Cancer 81 1999 1122 1126
108. J. Kwong, K.W. Lo, and K.F. To Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma Clin Cancer Res 8 2002 131 137 (Pubitemid 34101468)
109. S.M. Krishna, J. Kattoor, and P. Balaram Down regulation of adhesion protein E-cadherin in Epstein-Barr virus infected nasopharyngeal carcinomas Cancer Biomark 1 2005 271 277
110. L. Zhou, W. Jiang, and C. Ren Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues Neoplasia 7 2005 809 815
111. R.F. Ambinder, K.D. Robertson, and Q. Tao DNA methylation and the Epstein-Barr virus Semin Cancer Biol 9 1999 369 375
112. A.T. Chan, Q. Tao, and K.D. Robertson Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors J Clin Oncol 22 2004 1373 1381
113. Y. Hattori, M. Fukushima, and Y. Maitani Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth Int J Oncol 30 2007 1427 1439
114. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 2006 38 51
115. J. Gilbert, S.D. Gore, J.G. Herman, and M.A. Carducci The clinical application of targeting cancer through histone acetylation and hypomethylation Clin Cancer Res 10 2004 4589 4596
116. Vorinostat and azacitidine in treating patients with locally recurrent or metastatic nasopharyngeal cancer or nasal natural killer T-cell lymphoma. < http://www.clinicaltrials.gov > [accessed 19.02.10].
117. C. Keryer-Bibens, C. Pioche-Durieu, and C. Villemant Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1, the immunomodulatory protein galectin 9 BMC Cancer 6 2006 283
118. H. Zheng, L.L. Li, D.S. Hu, X.Y. Deng, and Y. Cao Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma Cell Mol Immunol 4 2007 185 196
119. N. Heussinger, M. Buttner, and G. Ott Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma J Pathol 203 2004 696 699
120. C. Munz, and A. Moormann Immune escape by Epstein-Barr virus associated malignancies Semin Cancer Biol 18 2008 381 387
121. X. Lin, N.H. Gudgeon, and E.P. Hui CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients Cancer Immunol Immunother 57 2008 963 975
122. J. Li, X.H. Zeng, and H.Y. Mo Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy PloS One 2 2007 e1122
123. D. Chua, J. Huang, and B. Zheng Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma Int J Cancer 94 2001 73 80
124. K.C. Straathof, C.M. Bollard, and U. Popat Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes Blood 105 2005 1898 1904
125. P. Comoli, P. Pedrazzoli, and R. Maccario Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes J Clin Oncol 23 2005 8942 8949
126. L. Wirth, M. Fogg, and F. Wang Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC) J Clin Oncol 27 2009 6025
127. Study of LMP1- and LMP2-specific cytotoxic T-lymphocytes (CTL) given with CD45 monoclonal antibody (MAb) in patients with Epstein Barr virus (EBV)-positive nasopharyngeal carcinoma (DELLA). < http://www.clinicaltrials. gov > [accessed 10.02.10].
128. C.L. Lin, W.F. Lo, and T.H. Lee Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma Cancer Res 62 2002 6952 6958
129. Vaccine therapy or observation in treating patients with nasopharyngeal cancer at high risk for recurrence. < http://www.clinicaltrials.gov > [accessed 10.02.10].
130. Peptide vaccine to prevent recurrence of nasopharyngeal cancer. < http://www.clinicaltrials.gov > [accessed 10.02.10].
131. Vaccine therapy and celecoxib in treating patients with metastatic nasopharyngeal cancer. < http://www.clinicaltrials.gov > [accessed 10.02.10].
132. S. Kamer, M. Esassolak, and D. Yalman Mature results of neoadjuvant chemotherapy followed by radiotherapy in nasopharyngeal cancer: is it really old fashioned? Med Oncol 25 2008 93 99
133. T.W. Leung, S.Y. Tung, and W.K. Sze Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns Head Neck 27 2005 555 565
134. Y. Zhang, Z.A. Lin, and J.J. Pan Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy Chin J Cancer 28 2009 1143 1148
135. A.W. Lee, W.T. Ng, and W.M. Hung Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors Int J Radiat Oncol 73 2009 1121 1128
136. A.W. Lee, W. Foo, and R. Chappell Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma Int J Radiat Oncol 40 1998 35 42
137. E.T. Wong, M. Huberman, X.Q. Lu, and A. Mahadevan Bevacizumab reverses cerebral radiation necrosis J Clin Oncol 26 2008 5649 5650
138. J. Gonzalez, A.J. Kumar, C.A. Conrad, and V.A. Levin Effect of bevacizumab on radiation necrosis of the brain Int J Radiat Oncol 67 2007 323 326
139. S.B. Schagen, M.J. Muller, and W. Boogerd Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients Ann Oncol 13 2002 1387 1397
140. V. Shilling, V. Jenkins, R. Morris, G. Deutsch, and D. Bloomfield The effects of adjuvant chemotherapy on cognition in women with breast cancer - preliminary results of an observational longitudinal study Breast 14 2005 142 150
141. L. Douw, M. Klein, and S.S. Fagel Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up Lancet Neurol 8 2009 810 818
142. B.W. Corn, M. Wang, and S. Fox Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03 J Neurooncol 95 2009 247 257
143. Gan H, Bernstein L, Brown J, et al. Neurocognitive outcomes of head and neck chemoradiotherapy: a pilot study. J Clin Oncol 2009;27(18s):6068 [abstract].
144. Hsiao KY, Yeh SA, Chang CC, et al. Cognitive function before and after intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: a prospective study. Int J Radiat Oncol; 2009 [Epub ahead of print].